MA-EVERBRIDGE
6.10.2020 22:12:09 CEST | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced additional top-tier Fortune 50 C-level executives, government officials and healthcare experts who have joined as speakers for its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006006062/en/
The latest speakers to join the Symposium include: retired Ford Motor Company Chief Executive Officer Jim Hackett, IBM President Jim Whitehurst, Mayo Clinic Platform Chief Medical Officer Clark C. Otley, M.D., Kaiser Permanente Associate Executive Director Stephen Parodi, MD, Los Angeles World Airports (LAWA) Chief Executive Officer Justin Erbacci, Goldman Sachs Chief Information Officer George Lee, Carlyle Group (CAG Holdings) Chief Strategy Officer Ginger Evans, Mississippi Governor Tate Reeves, Former Lieutenant Governor of Florida Carlos Lopez-Cantera, and Miami Mayor Francis Suarez. The event will also feature Gaurdie Banister, former President and CEO, Aera Energy LLC and Corporate Director of DOW, Russell Reynolds Associates, and Tyson Foods .
Each of these top speakers brings significant leadership experience managing some of the world’s largest and most iconic organizations, healthcare institutions and governments through the coronavirus pandemic and will cover topics related to global best practices to reopen economies, while most safely returning people to public spaces, offices, and campuses.
In addition to these top speakers, the two-day symposium will feature a former World Head of State , presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci , Virgin Group Founder Sir Richard Branson , and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta , as well as sessions with leading healthcare experts and government officials.
To attend the “COVID-19 R2R: The Road to Recovery” virtual leadership summit, please visit Everbridge’s event registration page .
“Everbridge provides key insights that public and private sector leaders need right now to navigate this next crucial phase of the coronavirus pandemic, to reopen economies while most safely returning people to public spaces, offices and campuses,” said Everbridge Chief Executive Officer David Meredith. “By leveraging our global partner and customer ecosystem, Everbridge continues to add top C-level leaders to our speaker lineup, as well as marquee keynotes including Dr. Anthony Fauci, Sir Richard Branson, Dr. Sanjay Gupta, and a former World Leader. While our most recent COVID-19 Symposium attracted well over 10,000 leaders across 150 countries, our current registrations remain on track to far exceed those numbers.”
The symposium will focus on the policies and actions organizations can take during the pandemic to keep people safe, execute contact tracing, return people to workplaces, campuses, and public spaces, protect supply chains, restore operations, and help organizations manage their reputations and communications to foster consumer safety and trust; all while managing across multiple critical events that could include hurricanes, wildfires, production stoppages, IT outages and cyberattacks.
To see a current list of speakers and register for the event, please visit here . Beyond the latest additions announced today, representative C-level speakers from Fortune 500 and international corporations also include a Fortune 25 Chief Executive Officer (CEO), Fortinet Founder, Chairman of the Board, and CEO Ken Xie, Accenture’s Arlin Pedrick, Auburn University’s President Jay Gogue, Aviva’s John Bernard, CAG Holdings’ Ginger Evans, Capital One’s William Baker, Fannie Mae’s Christopher Porter, Humana’s Stephan Pazienza, Lumen Technologies’ (formerly CenturyLink) Executive Vice President of Human Resources Scott Trezise, Optum’s Allison Miller, Rackspace Chief Legal and People Officer Holly Windham, and Siemens ’ Marco Mille, among others.
Speakers representing the healthcare and government sectors include Roberta Levy Schwartz, Ph.D., FACHE, Executive Vice President and Chief Innovation Officer at Houston Methodist and CEO of Houston Methodist Hospital ; Dr. Judy Monroe, Chief Executive Officer of the CDC Foundation ; Dr. Nancy Messonnier, Director of the Center for the National Center for Immunization and Respiratory Diseases (NCIRD ); Matt Roman, Chief Digital Strategy Officer of Duke University Health System ; Curt Wood, Chief Information Officer of the Commonwealth of Massachusetts ; Rebecca Baudendistel, Director of Public Warning at New York City Emergency Management Department ; Víðir Reynisson, Chief Superintendent of the Office of National Commission of Police in Iceland ; Benoît Vivier, European Union institutions liaison at the European Emergency Number Association (EENA) ; and Michael Hallowes, former National Director of Australia’s Emergency Alert program and Managing Director of Zefonar .
Over 5,300 global organizations use Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforce, rapidly communicate warnings, and protect supply chains. At the onset of the pandemic, Everbridge rapidly launched its COVID-19 Shield™ Return to Work and Contact Tracing software solutions followed by the introduction of Everbridge Control Center , the industry’s first off-the-shelf physical security information management software platform to help organizations return to work while complying with social distancing and Personal Protective Equipment (PPE) policies. Since the pandemic began, Everbridge customers have used its software to send more than 780 million coronavirus-related communications with vital information and instructions to safeguard their populations, employees, patients, and students.
Everbridge serves over 3,700 first responder agencies and 1,500 healthcare entities including the top pharmaceutical, biomedical and medical device and manufacturing companies, as well as the largest healthcare systems (overseeing more than 25 percent of all hospital beds in the U.S.), managed care organizations, pharmacies, and statewide health alert networks (HANs), including the CDC and the NIH.
The Everbridge Platform reaches over 600 million people and currently supports the countrywide public warning system deployments in all major regions of the world . Everbridge supports population-wide alerting in 11 countries across Europe, Asia, Oceania, The Middle East, Africa, and South America including Australia , Iceland , the Netherlands, New Zealand, Norway , Peru , Singapore and Sweden . Everbridge’s population alerting capabilities also power the entire states of California , Massachusetts , Vermont , New York , Connecticut , and Florida , as well as municipalities, counties and cities within 49 of the 50 United States, within all of Canada’s provinces, and throughout Europe and Asia, including deployments within multiple populous states in India .
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 14 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
